Genfit has discontinued development of its lead asset VS-01 in acute-on-chronic liver failure (ACLF) after a patient experienced peritonitis during a Phase 2 trial. The decision follows a data monitoring committee review and extensive safety considerations given the fragility of ACLF patients. Though the trial will not continue, Genfit plans ongoing preclinical evaluations in urea cycle disorder and will pursue other earlier-stage ACLF candidates with different mechanisms. The strategic move is expected to extend Genfit’s financial runway beyond 2028.